Novartis announces new analysis of Etresto for chronic heart failure

Hannah Alderton 16 April 2018

Novartis has announced a new post hoc analysis of the pivotal Phase III heart failure study, PARADIGM-HF, demonstrating that treatment with Entresto® (sacubitril/valsartan) helped to preserve kidney function in patients with heart failure with reduced ejection fraction (HFrEF). HFrEF patients treated with Entresto had a slower rate of decline in eGFR than those treated with ACE inhibitor enalapril. In a sub group of patients who had both HFrEF and diabetes, the magnitude of benefit was twice as high.

Non-diabetic HFrEF patients in the PARADIGM-HF study were shown to lose kidney function twice as fast as the general population. This was further accelerated in HFrEF patients with diabetes, who experienced a decline in kidney function that was twice as fast as the non-diabetic patients. When compared with enalapril, treatment with Entresto significantly slowed this decline in all HFrEF patients. In HFrEF patients who also had diabetes, the benefit of treatment with Entresto was doubled vs. those without diabetes.  

Heart failure is associated with both diabetes and kidney disease, which lead to poorer outcomes for patients, including increased risk of morbidity and mortality. More than half of all heart failure patients are expected to experience moderate to severe chronic kidney disease (CKD), and up to 40% of heart failure patients will have a diagnosis of diabetes. Diabetes significantly increases an individual's risk for CKD.

Primary data from PARADIGM-HF, the largest clinical trial ever conducted in heart failure, showed that treatment with Entresto reduced the risk of dying from a cardiovascular cause by 20%, reduced heart failure hospitalizations by 21% and reduced the risk of dying from any cause by 16% as compared to enalapril. A further post hoc analysis of PARADIGM-HF found that Entresto helped slow the rate of renal function decline, even in heart failure patients with chronic kidney disease, as compared to enalapril.

Shreeram Aradhye, Chief Medical Officer and Global Head, Medical Affairs, Novartis Pharmaceuticals said, "These results suggest that in addition to the established benefits on heart failure, Entresto treatment also helps to preserve kidney function. The benefit is particularly significant for people with chronic heart failure who also have diabetes"

Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.